Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis

Citation for published version:
Bowden, TA, Baruah, K, Coles, CH, Harvey, DJ, Yu, X, Song, B-D, Stuart, DI, Aricescu, AR, Scanlan, CN, Jones, EY & Crispin, M 2012, 'Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis', *Journal of the American Chemical Society*, vol. 134, no. 42, pp. 17554-63. https://doi.org/10.1021/ja306068g

Digital Object Identifier (DOI):
10.1021/ja306068g

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of the American Chemical Society

Publisher Rights Statement:
© 2012 American Chemical Society

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis

Thomas A. Bowden,*‡,†,‡,§ Kavitha Baruah,‡,⊥ Charlotte H. Coles,‡,⊥ David J. Harvey,‡ Xiaojie Yu,‡ Byeong-Doo Song,§ David I. Stuart,‡,|| A. Radu Aricescu,† Christopher N. Scanlan,‡ E. Yvonne Jones,† and Max Crispin*‡

Abstract: Human IgG Fc glycosylation modulates immunological effector functions such as antibody-dependent cellular cytotoxicity and phagocytosis. Engineering of Fc glycans therefore enables fine-tuning of the therapeutic properties of monoclonal antibodies. The N-linked glycans of Fc are typically complex-type, forming a network of noncovalent interactions along the protein surface of the Cd2 domain. Here, we manipulate the mammalian glycan-processing pathway to trap IgG1 Fc at sequential stages of maturation, from oligomannose- to hybrid- to complex-type glycans, and show that the Fc is structurally stabilized following the transition of glycans from their hybrid- to complex-type state. X-ray crystallographic analysis of this hybrid-type intermediate reveals that N-linked glycans undergo conformational changes upon maturation, including a flip within the trimannosyl core. Our crystal structure of this intermediate reveals a molecular basis for antibody biogenesis and provides a template for the structure-guided engineering of the protein–glycan interface of therapeutic antibodies.

Introduction

Antibodies are multifunctional glycoproteins, able to bind antigens through variable Fab domains and cellular receptors via the constant Fc region. This dual functionality enables the recruitment of the cellular immune system to sites of infection by antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and can lead to the localized activation of the complement system. Glycan and protein engineering of the Fc domain can generate therapeutic monoclonal antibodies with tailored receptor binding functionality.1,2 In contrast to chemical and chemoenzymatic methods to modulate glycan structures,3–9 we use glycosidase inhibitors and a cell line deficient in a glycosyltransferase to generate antibody glycoforms containing specific carbohydrate structures.

The Fc region of immunoglobulin G (IgG) is a homodimer consisting primarily of heavy chain Cd2 and Cd3 domains. The C-terminal Cd3 domain protomers interact through an extended protein–protein interface, occluding over 1100 Å2 of protein surface10 and adopt rigid conformations that exhibit little structural variation.11 In contrast, the Cd2 domain protomers have only been observed to interact via glycan–glycan contacts between opposing N-linked chains at Asn297.11–13 Glycan-mediated maintenance of the spacing between the Cd2 domains is critical for cellular Fcy receptor (FcyR) binding, which occurs asymmetrically at the tip of the Cd2 domains and lower hinge region.14 Deglycosylation, for example, by bacterial endoglycosidases, leads to disruption of Cd2 spacing and significantly impairs FcyR binding.15,16

The impact of Asn297 glycosylation upon Fc structure is not limited to influencing Cd2 spacing. IgG Fc glycosylation also stabilizes the protein through an approximately 500 Å2 glycan–protein interface along the surface of the Cd2 domain.11,13,17 These glycan–protein contacts are believed to limit both the processing by Golgi-resident glycosyltransferases and the conformational freedom of the glycan.18 This model is supported by an NMR study, which proposes that Fc glycans exist in an equilibrium with an approximately equal proportion of a “free” state, with highly mobile glycans, and a less mobile “bound” state, observable by X-ray crystallography, with...
ordered protein−glycan interactions less accessible to enzymatic processing. The composition of IgG Fc glycans is largely directed by the protein. The glycosylation exhibits limited processing and consists of a predominantly biantennary complex-type framework with partial occupancy of galactose, core α1→6-linked fucose, low levels of "bisecting" GlcNAc, and sialic acid. This limited processing is in contrast to the highly sialylated complex-type glycosylation typically observed on secreted glycoproteins.

The human FcγRs (FcγRI, FcγRIIa, FcγRIib, and FcγRIIIa) display binding properties dependent upon the presence and composition of the Fc glycan. For example, afucosylated antibody glycoforms, which may find utility in anticancer treatment, are inflammatory and exhibit enhanced ADCC due to elevated binding to the activatory FcγRIIIa. In contrast, anti-inflammatory IgG glycoforms display increased levels of terminal sialylation and are under investigation for enhanced intravenous immunoglobulin therapy.

Biosynthetic Fc precursors have also been investigated for therapeutic applications due to their altered FcγR-dependent effector functions. Monoclonal antibodies found in the early steps of carbohydrate maturation including oligomannose- or afucosylated hybrid-type glycans, for example, display increased affinity for FcγRIIIa and enhanced ADCC functionality, albeit with potentially elevated serum clearance. Here, we have generated and characterized a panel of such glycoform intermediates and present the crystal structure of the key precursor bearing hybrid-type glycosylation. In the context of the biosynthetic pathway of N-linked carbohydrates, this glycoform represents the intermediate formed between the immature oligomannose and the native, complex-type states. This Fc glycoform, generated by recombinant mammalian protein expression in the presence of the Golgi α-mannosidase II inhibitor, swainsonine, was crystallized and subjected to X-ray crystallographic analysis to 2.4 Å resolution. Examination of this structure reveals a novel interaction between carbohydrate and protein components. Together with thermolability analyses, the structure provides a model for the conformational transitions that IgG Fc undergoes upon glycoprotein maturation and provides a template for the structure-guided engineering of therapeutic antibodies.

### RESULTS AND DISCUSSION

**Expression and Purification of IgG Fc Glycoforms.** A panel of IgG1 Fc glycoforms, corresponding to key stages of the

---

**Figure 1.** The N-linked glycosylation processing pathway (left) and MALDI-TOF MS analysis of associated IgG1 Fc glycoforms (right). Following protein folding and hydrolysis of the glucose cap, glycoforms were isolated by stalling the pathway at sequential stages of biogenesis. (A) The Man9GlcNAc2 glycoform resulted from α-mannosidase (MI) inhibition with kifunensine. (B) The Man,GlcNAc glycoform resulted from expression in a GlcNAc transferase (GnT) I-deficient cell line. (C) Hybrid-type glycosylation resulted from expression in the presence of the Golgi α-mannosidase II (GMII) inhibitor, swainsonine. (D) Complex-type glycosylation resulted from activity of Golgi-resident glycosyltransferases. Ions are [M + Na]+. The sialylated glycan is also present as a sodium salt. The following symbols were used to represent glycans and are shown as a key in panel D: yellow ♦, galactose; blue ●, GlcNAc; green ○, Man; red ♦ with black dot, fucose; pink ★, sialic acid. Linkage positions are shown by the angle of the lines linking the sugar residues (vertical line, 2-link; forward slash, 3-link; horizontal line, 4-link; back slash, 6-link). Anomericy is indicated by unbroken lines for β-bonds and broken lines for α-bonds.
mammalian N-linked biosynthesis after calnexin/calreticulin-mediated protein folding, was generated using either a lectin-resistant cell line deficient in glycosyltransferase activity or by the use of glycosidase inhibitors (Figure 1).

We isolated IgG1 Fc bearing Man₉GlcNAc₂, Man₅GlcNAc₂, hybrid-, and complex-type glycans. These glycoforms are generally representative of the carbohydrates appearing in the ER, and the early, medial, and late Golgi apparatus, respectively. Glycan Analysis. The N-linked glycosylation of each Fc glycoform was assessed by positive ion matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) of enzymatically released glycans (Figure 1). Expression of Fc in the presence of the ER and Golgi α1→2-mannosidase inhibitor, kifunensine, resulted in a largely homogeneous Man₉GlcNAc₂ glycan (m/z = 1905.6; Figure 1A) with limited processing to the Man₅GlcNAc₂ derivative (m/z = 1743.6; Figure 1A). Expression of the Fc region in GnT I-deficient human embryonic kidney (HEK) 293S cells resulted in a similarly homogeneous spectrum dominated by Man₅GlcNAc₂ glycans (m/z = 1257.4; Figure 1B).

The next glycoform in the N-linked biosynthetic pathway, the hybrid-type glycan, was isolated using the Golgi α1→2-mannosidase II inhibitor, swainosine. Swainosine prevents hydrolysis of the ManA and ManB saccharides of the “6-arm” of the trimannosyl core. However, this inhibition does not impede the addition of a GlcNAc residue to the “3-arm” Man₄ by GnT I or subsequent structural elaborations. Consistent with this mode of action, MALDI-TOF MS analysis of the N-linked glycans of IgG1 Fc expressed with 10 μM swainosine revealed a heterogeneous spectrum of putative hybrid-type glycans indicating variable terminal β1→4-linked galactose, “bisecting” β1→4-linked GlcNAc, and a population of sialylated hybrid-type glycans (m/z = 2081.7; Figure 1C). Finally, Fc bearing complex-type glycans were generated using HEK 293T cells with no inhibitors present. MALDI-TOF MS analysis revealed biantennary complex-type glycans with variable terminal galactose (Figure 1D). This spectrum is consistent with previous observations that Fc glycosylation is highly protein-directed and substantially less processed than other glycoproteins similarly expressed using the pHlSec expression vector in HEK 293T cells.

Levels of both galactose and sialic acid in the hybrid-type spectrum were higher than those observed for the complex-type glycoforms. As sialic acid can alter the ionization efficiency of glycans in mass spectrometry, we also subjected the hybrid and complex-type glycans to electrospray ionization (ESI) mass spectrometry (Figure 2). No sialylated structures were detected by ESI–MS of the glycans released from the Fc glycoform bearing complex-type glycans (Figure 2B). In contrast, the spectrum of glycans deriving from Fc expressed in the presence of swainosine contained a prominent peak at m/z 2035.7 corresponding to a sialylated core-fucosylated hybrid-type glycan (Figure 2A).

Isomeric assignments of the hybrid-type structures were determined by negative-ion ESI–MS–MS of the enzymatically released glycans. The fragmentation spectra of the most abundant species are presented in Figure 3. The m/z values of the “D-type ions”, as defined by Harvey, are a signature of the 6-arm. These D-type ions are annotated in the spectra and are formed by the formal loss of the 3-arm and the fucosylated di-N-acetylchitobiose core. Similarly, the D′-type ions, formed by cleavage of the 6-arm, reveal the cluster of mannose residues on the 6-arm. Bisecting GlcNAc residues are revealed by an abundant [D = 221]⁻ ion at m/z 629 and the virtual absence of a D-type ion. This absence of an ion at m/z 306 shows that the sialic acid residue is α2→6-linked (Figure 3A). This linkage contrasts α2→6-linked sialic acid observed in serum-derived antibodies.

To assess the level of sialic acid in the hybrid-type glycans, we expressed intact IgG1 antibody hybrid-type glycoform and subjected the fluorescently derivatized glycans to normal-phase HPLC. This analysis revealed that 20% of these swainosine-induced hybrid-type glycans were sialylated (Figure 4A). Consistent with our MALDI–MS and ESI–MS data of IgG1 Fc glycans, no sialylated structures were observed in IgG in the presence of swainosine (Figure 4B).

Swainosine is not known to affect galactosyltransferase or sialyltransferase activity, as confirmed by the similar glycan profiles of the same glycoproteins expressed in HEK 293T cells.

Figure 2. Negative ion electrospray mass spectra of recombinant IgG1 Fc N-linked glycans following expression in the (A) presence and (B) absence of the Golgi α1→2-mannosidase II inhibitor, swainosine. Neutral glycan ions are \([M + H_2PO_4]^-\), sialylated glycans are \([M − H]^+.\) Symbols for the structures are as described in Figure 1. Isomeric assignments were determined by ESI–MS/MS (Figure 3). The presence of a minor population of Man₅-based hybrids was detected in the fragmentation spectra by very low abundance \(^{1,3}A_3\) ions at m/z 424 (Figure 3B,D).
Figure 3. Negative ion fragmentation spectra of the major N-linked glycans from the hybrid-type glycoform of IgG1 Fc. Neutral glycan ions are \([M + H_2PO_4^-]\), while the sialylated glycan forms a \([M - H]^+\) ion. (A) Sialylated, fucosylated hybrid glycan (Man$_5$Gal$_1$GlcNAc$_3$Fuc$_1$NeuNAc$_1$), $m/z$ 2035.7. (B) Bi- and fucosylated hybrid glycan (Man$_5$GlcNAc$_4$Fuc$_1$), $m/z$ 1883.6. (C) Fucosylated hybrid glycan (Man$_5$Gal$_1$GlcNAc$_3$Fuc$_1$), $m/z$ 1842.6. (D) Agalactosylated, fucosylated hybrid glycan (Man$_5$GlcNAc$_3$Fuc$_1$), $m/z$ 1680.5. The nomenclature describing fragmentation ions follows that of Domon and Costello$^{45}$ and is distinct from the carbohydrate residue labels (Figure 1).

Figure 4. HPLC analysis of fluorescently labeled N-linked glycans from recombinant IgG1 expressed in HEK 293T cells in (A) the presence and (B) the absence of the GnT I inhibitor, swainsonine. The lower panels show the spectra of glycans following digestion with *Arthrobacter ureafaciens* sialidase. Symbols for the structures are as described in Figure 1.
in the presence of swainsonine and in HEK 293T Lec36 cells that are devoid of Golgi α-mannosidase II activity.38 Similarly, there was no evidence of increased terminal processing upon disruption of Golgi α-mannosidase II activity as compared to glycoproteins expressed in HEK 293T cells.38 Therefore, the increased abundance of galactose and sialic acid residues in the 3-arm of the hybrid-type glycoform, as compared to the complex glycoform, may be indicative of increased steric accessibility of the Fc glycans to processing enzymes.

Thermodynamic Stability of Fc Glycoforms. One explanation for the increased 3-arm processing of the hybrid-type glycoform as compared to that of the complex-type glycan is that the accessibility of the glycans is influenced by composition and structure of the glycan–protein interface. Because of the highly processed composition of the hybrid-type glycoform, we hypothesized it would exhibit distinct glycan–protein packing interactions with altered stability. We assessed our panel of Fc glycoforms by diﬀerential scanning fluorimetry (Figure 5).

This analysis revealed that relative to the melting temperature (Tm) of the complex-type glycoform, the other glycoforms exhibited reduced Tm values: ManαGlCNAC2 (Tm = −2.8 ± 0.7 °C), hybrid-type glycoforms (Tm = −4.0 ± 0.7 °C), and endoglycosylated-treated Fc (−5.2 ± 1.0 °C). Therefore, in addition to reducing glycan accessibility to glycosyltransferases, the enzymatic action of Golgi α-mannosidase II, to produce complex-type glycans, is permissive for the biosynthesis of a more thermally stabilized Fc structure. We sought to investigate the structural basis for this observation by X-ray crystallography.

Structural Characterization of the Hybrid-Type Fc Glycoform. Crystallographic structures of IgG Fc have been reported for a number of glycoforms ranging from oligomannose ManαGlCNAC2 to homogeneous complex-type, and endoglycosidase-deactivated and aglycosylated states.11,15,37,46 However, no crystallographic information is available for the hybrid-type Fc glycoform that represents the transition state between oligomannose and complex-type glycosylation states.11 Therefore, the accessibility of the glycans is influenced by composition and structure of the glycan–protein interface. Because of the highly processed composition of the hybrid-type glycoform, we hypothesized it would exhibit distinct glycan–protein packing interactions with altered stability. We assessed our panel of Fc glycoforms by differential scanning fluorimetry (Figure 5).

Table 1. Crystallographic Data and Refinement Statistics

<table>
<thead>
<tr>
<th>Data Collection</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>beamline</td>
<td>BM-14</td>
</tr>
<tr>
<td>resolution range (Å)</td>
<td>50.0–2.36 (2.42–2.36)</td>
</tr>
<tr>
<td>space group</td>
<td>P212121</td>
</tr>
<tr>
<td>cell dimensions</td>
<td>a, b, c (Å)</td>
</tr>
<tr>
<td></td>
<td>49.0, 72.9, 140.8</td>
</tr>
<tr>
<td></td>
<td>90.0, 90.0, 90.0</td>
</tr>
<tr>
<td>wavelength (Å)</td>
<td>0.953</td>
</tr>
<tr>
<td>unique reflections</td>
<td>21 447 (2094)</td>
</tr>
<tr>
<td>completeness (%)</td>
<td>99.3 (98.7)</td>
</tr>
<tr>
<td>Rmerge (%)</td>
<td>9.9 (65.3)</td>
</tr>
<tr>
<td>I/σ(I)</td>
<td>16.5 (2.4)</td>
</tr>
<tr>
<td>avg redundancy</td>
<td>4.8 (4.5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Refinement</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>resolution range (Å)</td>
<td>40.0–2.36 (2.42–2.36)</td>
</tr>
<tr>
<td>no. of reflections</td>
<td>21 379 (1459)</td>
</tr>
<tr>
<td>Rmerge (%)</td>
<td>21.5</td>
</tr>
<tr>
<td>Rfree (%)</td>
<td>26.6</td>
</tr>
<tr>
<td>rmsd bonds (Å)</td>
<td>0.006</td>
</tr>
<tr>
<td>angles (deg)</td>
<td>1.2</td>
</tr>
<tr>
<td>molecules per asu</td>
<td>1</td>
</tr>
<tr>
<td>atoms per asu</td>
<td>3183/93/218</td>
</tr>
<tr>
<td>average B-factors (Å²)</td>
<td>43.2/44.7/36.8</td>
</tr>
<tr>
<td>model quality (Ramachandran plot)</td>
<td>99.5</td>
</tr>
<tr>
<td>most favored region (%)</td>
<td>99.5</td>
</tr>
<tr>
<td>allowed region (%)</td>
<td>0.5</td>
</tr>
</tbody>
</table>

*Numbers in parentheses refer to the relevant outer resolution shell.

**Rmerge = \(\sum_{i} I(hkli) - \langle I(hkli) \rangle / \sum_{i} \langle I(hkli) \rangle\), where \(I(hkli)\) is the intensity of an individual measurement and \(\langle I(hkli) \rangle\) is the average intensity from multiple observations.

Rfree was calculated as for Rwork, but using only 5% of the data, which were sequestered prior to refinement. *rmsd: root-mean-square deviation from ideal geometry. **asu: asymmetric unit. *Ramachandran plots were calculated with Molprobity. 39

Figure 5. Thermodynamic stability of IgG1 Fc glycoforms. Single thermostability measurements of oligomannose (ManαGlCNAC2), hybrid, and complex-type glycoforms are shown. Measurements were performed in triplicate.
When carbohydrates are modified are illustrated by the hydrolysis of terminal α1→2 mannose residues of the ManαGlcNAc2 glycoform. The ManD3 residue in the ManαGlcNAc2 structure anchors the oligosaccharide chain to the protein surface at the junction of the C2 and C3 domains (Figure 7A). As the solvent-accessible ManD1 and ManD2 residues are disordered in the crystal structure,47 hydrolysis of ManD3 is likely to induce the observed rearrangement of the 6-arm and cause the 6 Å shift of ManB (Figure 7A,B). This cleavage also results in the associated relaxation of the Man4′α1→6Man3 linkage (from ϕ = 69°, ψ = −178°, ω = 62° to ϕ = 77°, ψ = 101°, ω = 30°; Figure 7A,B). Despite this movement, the Man4′ residue in the ManαGlcNAc2 glycoform is orientated in a direction opposite to that of complex-type structures (Figure 7C). This orientation is maintained by the presence of ManA and ManB residues of the 6-arm that sterically prevent further rotation of the Man4′α1→6Man3 linkage (Figure 7B).

**Transition from ManαGlcNAc2 to Hybrid-Type.** The action of GnT I on ManαGlcNAc2 catalyzes the formation of hybrid-type glycans and allows downstream carbohydrate processing (Figure 1). GnT I transfers β1→2-linked GlcNAc to the Man4 residue of the 3-arm to form the GlcNAc5β1→2Man4 linkage (Figure 7B,C). As for many structures of complex-type glycoforms, we do not observe interpretable electron density for the solvated and mobile residues on this arm. Additionally, GnT I catalysis also renders the core GlcNAc residue (GlcNAc1) of the hybrid-type glycan susceptible to α1→6-fucosylation.36 We observe electron density for the fucose and note the conformation closely resembles that of the complex-type glycoform (Figure 7B,C). This supports our assertion that ManαGlcNAc2 glycans are not affected structurally by fucosylation.

**Formation of Complex-type Glycans.** Golgi α-mannosidase II hydrolyses the α1→3-linked ManA and α1→6-linked ManB residues from the 6-arm and is dependent upon the prior activity of GnT I (Figure 1). Elimination of these residues relieves steric restraints around the 6-arm and allows the reorientation of the Man4′α1→6Man3 linkage (from ϕ = 77°, ψ = 101°, ω = 30° to ϕ = 62°, ψ = 171°, ω = −175°; Figure 7B,C), causing close alignment of the glycan to the protein surface.

Following this rearrangement, GnT II catalyzes the transfer of β1→2-linked GlcNAc to Man4′, allowing the formation of hydrophobic stacking interactions between GlcNAc5′ and Phe243 (Figure 7C). The formation of these canonical glycan–protein interactions is consistent with the increased stability7 (Figure 5 and Supporting Information Figure S1) and decreased enzymatic processing of the mature complex-type glycoform relative to the artificially trapped hybrid-type glycoform (Figures 1, 2, and 4). Limited downstream compositional heterogeneity of the complex-type glycoform subsequently arises from the partial transfer of galactose to terminal GlcNAc5 and GlcNAc5′ residues8 and leads to little change with respect to carbohydrate conformation or thermal stability.11,17

Evidence for the suppression of galactosylation and sialylation by the interaction between GlcNAc5′ and Phe243 is provided by the analysis of IgG from a patient with a homozygous mutation in the Mgat2 gene.30 Mgat2 encodes GnT II that catalyzes the transfer of the 6-arm GlcNAc5′ to Man4′. The IgG Fc glycans isolated from the patient lacked 6-arm GlcNAc5′ but exhibited significantly elevated 3-arm

---

**Figure 6.** Crystal structure of the hybrid-type glycoform of human IgG1 Fc. (A) The Fc structure with the protein moiety shown as a gray ribbon with the N-linked glycan of N297 shown as sticks. Carbohydrate residues are colored and labeled as in Figure 1. A maximum likelihood weighted 2Fo − Fc electron density map is plotted around the glycan at 1σ. (B) Panel A rotated 70° with a close-up view of the protein and carbohydrate components of the Cγ2 domain from chain A of the hybrid Fc crystal structure. No electron density was observed for the processed 3-arm beyond Man4. (C) Overlay of the protein backbone of the hybrid (gray), oligomannose (cyan; PDB accession code 2WAH), and complex-type (pink; PDB accession code 3AVE) glycoforms. (D) The overlay in panel C rotated 90° with a dashed line corresponding to a 17 Å distance between equivalent Ser298 Cα atoms in the hybrid- and complex-type glycoforms.
processing as compared to wild-type structures with the majority of glycans containing the NeuNAc α2→6Gal β1→4GlcNAc motif. Together with our structural observations, we suggest that the action of Golgi α-mannosidase II and GnT II enhance the glycan–protein interface and limit glycosyltransferase accessibility to the 3-arm.

■ SUMMARY AND CONCLUSIONS

The use of glycosidase inhibitors and cell-lines with genetically modified glycan processing enzymes offers a powerful route to the isolation of glycoproteins with defined glycan structures. These methods offer an attractive alternative to direct chemical synthesis and can be readily combined with chemoenzymatic methodologies.

Analysis of isolated biosynthetic intermediates of IgG1 Fc revealed distinct differences in the susceptibility of discrete glycan states to glycosyltransferases. Specifically, we have shown by mass spectrometry that the trapped hybrid-type glycans are more readily accessible to galactosyl and sialyltransferases than are complex-type structures. The generation of hybrid-type glycoforms with increased Fc sialylation is of note given the enhanced anti-inflammatory functionality exhibited by sialylated Fc in, for example, intravenous immunoglobulin therapy.

The biosynthetic intermediates also exhibited reduced stability, an important parameter in the development of antibody therapeutics. Through our X-ray crystallographic analysis, we correlate this stability to structural transitions that occur during antibody biogenesis. We offer a molecular-level explanation for how stability arises from rearrangements of the glycan–protein interface. We deduce that glycan-dependent stabilization occurs during Golgi α-mannosidase II and GnT II processing, which respectively cause the relaxation of the 6-arm toward the protein surface and the formation of hydrophobic glycan–protein interfaces.

Given the promising portfolio of effector functions exhibited by IgG bearing oligomannose and hybrid-type glycans, knowledge of their three-dimensional structure and defined molecular transitions provides a template to support structure-guided stabilization and optimization for the clinic.

■ EXPERIMENTAL PROCEDURES

Protein Expression and Purification. The Fc region of human IgG1 (residues 120–329, GenBank accession no. J00228) was cloned into the pHLSec vector and transiently expressed in HEK 293T cells (ATCC number CRL-1573), GnT I-deficient HEK 293S cells, and in the presence of mannosidase inhibitors to isolate glycoforms of distinct composition. Transfections were performed using 2 mg of DNA per liter cell culture medium as previously described. Fc bearing Man9GlcNAc2 and hybrid-type glycosylation were obtained by expression in the presence of 20 and 10 μM of the inhibitors, kifunensine and swainsonine, respectively (Toronto Research.
Chemicals, Canada). Inhibitors were added at the time of transfection, and the supernatants were harvested after 5 days. IgG1 Fc glycoproteins were purified at room temperature by immobilized metal-affinity chromatography (GE Healthcare, Bucks, UK) and size exclusion chromatography using a Superdex 200 10/30 column (Amersham, Bucks, UK), in a buffer containing 150 mM NaCl and 10 mM Tris pH 7.4. Yields were typically 20 mg of purified IgG1 Fc per liter cell culture.

Plasmids encoding IgG1 b12 light and heavy chains were kindly provided by Professor Dennis Burton (The Scripps Research Institute, CA). The heavy and light chains were transiently cotransfected in HEK 293T cells in the presence or absence of 100 μg of plasmid. Yields were typically 8 mg of purified IgG1 b12 per liter cell culture.

Thermodynamic Stability of IgG1 Fc Glycoforms. The thermal stability of different Fc glycoforms was assessed by differential scanning fluorimetry using a Stratagene RT PCR 305 instrument. Thermally induced unfolding of purified Fc glycoforms was monitored, in triplicate, by measuring Absorbance at 610 nm at 1.5 °C increments in the presence of Sypro Orange (Invitrogen, Paisley, UK), a fluorescent stain sensitive to hydrophobic environments.

Nomenclature. Throughout this work, we have adopted the system of Vliegenthart et al. for labeling residues within oligomannose- and biantennary-type oligosaccharides with the additional modifications of 7 °C and 7° for sialic acid, 1° for α1→6-linked core fucose (Figure 1). These residue labels are in bold-face throughout this Article. The symbolic representation of glycans follows that of the Centre for Glycomics.

ASSOCIATED CONTENT

Supporting Information

Atomic coordinates and crystallographic structure factors of IgG1 Fc bearing hybrid-type glycans have been deposited in the Protein Data Bank (PDB) with accession code 4B7I. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

thomas.bowden@strubi.ox.ac.uk; max.crispin@bioch.ox.ac.uk

Author Contributions

These authors contributed equally.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This Article is dedicated to the memory of James Franz and Nigel Botting. We thank the staff of beamline BM14 at the European Synchrotron Radiation Facility and Karl Harlos, Tom Walter, Weixian Lu, and David Stauton for helpful advice and technical support. We also gratefully acknowledge Prof. James Scrivens, University of Warwick, UK, for access to the Waters Synapt G2 mass spectrometer. We thank Raymond Dwek and Ian Wilson for their support. T.A.B. is a Sir Henry Wellcome Postdoctoral Fellow (Grant Number 089026/Z/09/Z) and Junior Research Fellow at University College, Oxford. M.C. is a Fellow of Oriel College, Oxford. E.Y.J. is a Cancer Research UK